These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17568278)

  • 1. Reducing diabetes incidence through the inhibition of the renin-angiotensin system: a strategy for reducing cardiovascular mortality and morbidity?
    Zanolla L; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2007 Jul; 8(7):473-82. PubMed ID: 17568278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R; Brown DL
    Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-Angiotensin-Aldosterone system inhibition in prevention of diabetes mellitus.
    Bălută M; Vintilă V; Vintilă M
    Rom J Intern Med; 2004; 42(2):277-88. PubMed ID: 15529618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the role of angiotensin-receptor blockade in cardiovascular protection?
    Cohn JN
    Am Heart J; 2006 Nov; 152(5):859.e1-8. PubMed ID: 17070145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renin angiotensin system as a therapeutic target to prevent diabetes and its complications.
    Vijayaraghavan K; Deedwania PC
    Cardiol Clin; 2005 May; 23(2):165-83. PubMed ID: 15694745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
    Perkins JM; Davis SN
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):147-52. PubMed ID: 18316950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
    Hershon KS
    Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.